Try our beta test site

Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Connecticut Children's Medical Center
Sponsor:
Information provided by (Responsible Party):
Olga Salazar, Connecticut Children's Medical Center
ClinicalTrials.gov Identifier:
NCT01671696
First received: August 21, 2012
Last updated: February 13, 2017
Last verified: February 2017
  Purpose
The main hypothesis being tested is that imaging and serologic biomarkers of apoptosis and progressive extracellular matrix remodeling will precede echocardiographic indices of systolic and diastolic function among childhood cancer survivors treated with anthracyclines thus allowing evaluation of new therapies to prevent and manage heart failure in these patients.

Condition Intervention
Cardiovascular Disease
Other: Cardiac MRI

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy: A Cardiac Magnetic Resonance and Biomarker Imaging and Serological Biomarker Study

Further study details as provided by Connecticut Children's Medical Center:

Primary Outcome Measures:
  • To see if a CMRI is better at detecting occult asymptomatic cardiotoxicity [ Time Frame: 1 year ]
    Changes in T1 mapping-derived relaxation time and left ventricular myocardial peak circumference strain are present in asymptomatic post-chemotherapy pediatric patients who have normal standard CMRI parameters. Circumferential strain analysis and measurement of the T1 myocardial relaxation time by CMRI may accurately identify occult cardiovascular dysfunction in patients exposed to high dose anthracyclines.


Secondary Outcome Measures:
  • Have a low shortening fraction is an indicator of cardiotoxicity [ Time Frame: 1 year ]
    Shortening Fraction < 29% during chemotherapy or at follow-up, even if transient, serves as an early marker for cardiotoxicity (Lower EF, LV Mass, and increased ESWS).


Estimated Enrollment: 80
Study Start Date: September 2011
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Cardiac MRI
    Cardiac MRI
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   9 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Survivors of childhood cancer who were treated with anthracyclines and are greater than 2 years from their last cycle of chemotherapy
Criteria

Inclusion Criteria:

  • Childhood cancer survivors from the late effect clinic who had been in continuous, complete remission and off chemotherapy for a minimum of 2 years.
  • Age > 9 years of age

Exclusion Criteria:

  • Contraindications to CMRI
  • Relapse of their cancer
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01671696

Locations
United States, Connecticut
Connecticut Children's Medical Center Recruiting
Hartford, Connecticut, United States, 06106
Contact: Nancy Cronin    860-837-5881      
Sponsors and Collaborators
Connecticut Children's Medical Center
Investigators
Principal Investigator: Olga Salazar, MS Connecticut Childrens Med Ctr
  More Information

Responsible Party: Olga Salazar, Assistant Clinical Professor, Pediatric Cardiology, Connecticut Children's Medical Center
ClinicalTrials.gov Identifier: NCT01671696     History of Changes
Other Study ID Numbers: 10-096 CCMC 
Study First Received: August 21, 2012
Last Updated: February 13, 2017
Individual Participant Data  
Plan to Share IPD: Undecided
Plan Description: pending PI review.

Additional relevant MeSH terms:
Cardiovascular Diseases
Cardiotoxicity
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries

ClinicalTrials.gov processed this record on February 27, 2017